Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

Mridul Datta, Paul Savage, James Lovato, Gary G. Schwartz

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

Original languageEnglish (US)
Pages (from-to)2205-2214
Number of pages10
JournalFuture Oncology
Volume12
Issue number19
DOIs
StatePublished - Oct 2016

Fingerprint

Serum Albumin
Calcium
Neoplasms
Disease Progression
Albumins
Melanoma
Serum
Cross-Sectional Studies
Odds Ratio
Cutaneous Malignant Melanoma

Keywords

  • Albumin
  • Albumin-corrected calcium
  • Malignant melanoma
  • Serum calcium

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum calcium, albumin and tumor stage in cutaneous malignant melanoma. / Datta, Mridul; Savage, Paul; Lovato, James; Schwartz, Gary G.

In: Future Oncology, Vol. 12, No. 19, 10.2016, p. 2205-2214.

Research output: Contribution to journalReview article

Datta, Mridul ; Savage, Paul ; Lovato, James ; Schwartz, Gary G. / Serum calcium, albumin and tumor stage in cutaneous malignant melanoma. In: Future Oncology. 2016 ; Vol. 12, No. 19. pp. 2205-2214.
@article{88109b3574174d4993064e3f9b4b80b6,
title = "Serum calcium, albumin and tumor stage in cutaneous malignant melanoma",
abstract = "Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95{\%} CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60{\%} for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.",
keywords = "Albumin, Albumin-corrected calcium, Malignant melanoma, Serum calcium",
author = "Mridul Datta and Paul Savage and James Lovato and Schwartz, {Gary G.}",
year = "2016",
month = "10",
doi = "10.2217/fon-2016-0046",
language = "English (US)",
volume = "12",
pages = "2205--2214",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "19",

}

TY - JOUR

T1 - Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

AU - Datta, Mridul

AU - Savage, Paul

AU - Lovato, James

AU - Schwartz, Gary G.

PY - 2016/10

Y1 - 2016/10

N2 - Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

AB - Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

KW - Albumin

KW - Albumin-corrected calcium

KW - Malignant melanoma

KW - Serum calcium

UR - http://www.scopus.com/inward/record.url?scp=84988649543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988649543&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0046

DO - 10.2217/fon-2016-0046

M3 - Review article

C2 - 27306120

AN - SCOPUS:84988649543

VL - 12

SP - 2205

EP - 2214

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 19

ER -